HCPCS J9020: Asparaginase Injection, 10,000 Units
Commercial payers pay $62 on average nationally for this procedure.
HCPCS Level II code J9020 describes an injection of asparaginase, supplied as 10,000 units, used as a chemotherapeutic agent; the service is administration of the medication, typically delivered in an infusion or injection setting such as an outpatient oncology clinic or hospital infusion center.
Customize your policy alerts
Sign up for hcpcs J9020 policy alerts
Get alerted when payer policies referencing J9020 are released or updated.
Monitor payer policy activity
National Reimbursement Benchmarks
National commercial rates for J9020 cluster around BUCA’s average commercial benchmark of $61.8, with notable variation among major insurers. Blue Cross Blue Shield centers near its own high mean of $62.0 and a median of $65.8, while Cigna and UnitedHealth Group sit well above BUCA’s average with means of $76.4 and $83.4 respectively; Cigna’s median is $77.9 and UnitedHealth Group’s median is $77.5. Aetna is materially lower, with a mean of $25.0 and a median of $12.4, indicating a distinct lower-cost segment in the market.
Dispersion measured by the interquartile range (P75 minus P25) is tightest for Blue Cross Blue Shield at $12.2 (P75 $67.9 minus P25 $56.7) and for Cigna at $16.3 (P75 $84.3 minus P25 $67.0). The widest spread appears with UnitedHealth Group at $10.9 (P75 $81.9 minus P25 $73.1) and BUCA shows a spread of $15.9 (P75 $69.1 minus P25 $53.1). Aetna’s spread is $36.4 (P75 $44.9 minus P25 $8.6), the most pronounced variability among the listed payers.